RU2397757C2 - Чрескожный лекарственный препарат для лечения болезни паркинсона, содержащий сочетания действующих веществ - Google Patents
Чрескожный лекарственный препарат для лечения болезни паркинсона, содержащий сочетания действующих веществ Download PDFInfo
- Publication number
- RU2397757C2 RU2397757C2 RU2005141214/15A RU2005141214A RU2397757C2 RU 2397757 C2 RU2397757 C2 RU 2397757C2 RU 2005141214/15 A RU2005141214/15 A RU 2005141214/15A RU 2005141214 A RU2005141214 A RU 2005141214A RU 2397757 C2 RU2397757 C2 RU 2397757C2
- Authority
- RU
- Russia
- Prior art keywords
- combination
- group
- active substances
- drug according
- receptor antagonist
- Prior art date
Links
- 239000013543 active substance Substances 0.000 title claims abstract description 94
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 229940079593 drug Drugs 0.000 title claims abstract description 29
- 208000018737 Parkinson disease Diseases 0.000 title claims abstract description 24
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 claims description 27
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 claims description 26
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 claims description 26
- 229960003946 selegiline Drugs 0.000 claims description 24
- 239000003136 dopamine receptor stimulating agent Substances 0.000 claims description 18
- -1 pyribedil Chemical compound 0.000 claims description 12
- 229940121948 Muscarinic receptor antagonist Drugs 0.000 claims description 9
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- SHXWCVYOXRDMCX-UHFFFAOYSA-N 3,4-methylenedioxymethamphetamine Chemical compound CNC(C)CC1=CC=C2OCOC2=C1 SHXWCVYOXRDMCX-UHFFFAOYSA-N 0.000 claims description 6
- 229940086616 Monoamine oxidase B inhibitor Drugs 0.000 claims description 6
- 229940052760 dopamine agonists Drugs 0.000 claims description 6
- 229960003179 rotigotine Drugs 0.000 claims description 6
- KFQYTPMOWPVWEJ-INIZCTEOSA-N rotigotine Chemical compound CCCN([C@@H]1CC2=CC=CC(O)=C2CC1)CCC1=CC=CS1 KFQYTPMOWPVWEJ-INIZCTEOSA-N 0.000 claims description 6
- 229940099433 NMDA receptor antagonist Drugs 0.000 claims description 5
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 5
- 239000000150 Sympathomimetic Substances 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 229960003089 pramipexole Drugs 0.000 claims description 4
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 claims description 4
- 229960001879 ropinirole Drugs 0.000 claims description 4
- UHSKFQJFRQCDBE-UHFFFAOYSA-N ropinirole Chemical compound CCCN(CCC)CCC1=CC=CC2=C1CC(=O)N2 UHSKFQJFRQCDBE-UHFFFAOYSA-N 0.000 claims description 4
- WYDUSKDSKCASEF-LJQANCHMSA-N (1s)-1-cyclohexyl-1-phenyl-3-pyrrolidin-1-ylpropan-1-ol Chemical compound C([C@](O)(C1CCCCC1)C=1C=CC=CC=1)CN1CCCC1 WYDUSKDSKCASEF-LJQANCHMSA-N 0.000 claims description 3
- KORNTPPJEAJQIU-KJXAQDMKSA-N Cabaser Chemical compound C1=CC([C@H]2C[C@H](CN(CC=C)[C@@H]2C2)C(=O)N(CCCN(C)C)C(=O)NCC)=C3C2=CNC3=C1 KORNTPPJEAJQIU-KJXAQDMKSA-N 0.000 claims description 3
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 claims description 3
- JOAHPSVPXZTVEP-YXJHDRRASA-N Terguride Chemical compound C1=CC([C@H]2C[C@@H](CN(C)[C@@H]2C2)NC(=O)N(CC)CC)=C3C2=CNC3=C1 JOAHPSVPXZTVEP-YXJHDRRASA-N 0.000 claims description 3
- HWHLPVGTWGOCJO-UHFFFAOYSA-N Trihexyphenidyl Chemical group C1CCCCC1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 HWHLPVGTWGOCJO-UHFFFAOYSA-N 0.000 claims description 3
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims description 3
- 229960003805 amantadine Drugs 0.000 claims description 3
- 229960004046 apomorphine Drugs 0.000 claims description 3
- VMWNQDUVQKEIOC-CYBMUJFWSA-N apomorphine Chemical compound C([C@H]1N(C)CC2)C3=CC=C(O)C(O)=C3C3=C1C2=CC=C3 VMWNQDUVQKEIOC-CYBMUJFWSA-N 0.000 claims description 3
- 229960002802 bromocriptine Drugs 0.000 claims description 3
- OZVBMTJYIDMWIL-AYFBDAFISA-N bromocriptine Chemical compound C1=CC(C=2[C@H](N(C)C[C@@H](C=2)C(=O)N[C@]2(C(=O)N3[C@H](C(N4CCC[C@H]4[C@]3(O)O2)=O)CC(C)C)C(C)C)C2)=C3C2=C(Br)NC3=C1 OZVBMTJYIDMWIL-AYFBDAFISA-N 0.000 claims description 3
- 229960004596 cabergoline Drugs 0.000 claims description 3
- 229960004205 carbidopa Drugs 0.000 claims description 3
- TZFNLOMSOLWIDK-JTQLQIEISA-N carbidopa (anhydrous) Chemical compound NN[C@@](C(O)=O)(C)CC1=CC=C(O)C(O)=C1 TZFNLOMSOLWIDK-JTQLQIEISA-N 0.000 claims description 3
- JRURYQJSLYLRLN-BJMVGYQFSA-N entacapone Chemical compound CCN(CC)C(=O)C(\C#N)=C\C1=CC(O)=C(O)C([N+]([O-])=O)=C1 JRURYQJSLYLRLN-BJMVGYQFSA-N 0.000 claims description 3
- 229960003337 entacapone Drugs 0.000 claims description 3
- 229960003587 lisuride Drugs 0.000 claims description 3
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical compound C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 3
- 229960004640 memantine Drugs 0.000 claims description 3
- 239000003697 methyltransferase inhibitor Substances 0.000 claims description 3
- 229960005103 metixene Drugs 0.000 claims description 3
- MJFJKKXQDNNUJF-UHFFFAOYSA-N metixene Chemical compound C1N(C)CCCC1CC1C2=CC=CC=C2SC2=CC=CC=C21 MJFJKKXQDNNUJF-UHFFFAOYSA-N 0.000 claims description 3
- JCSREICEMHWFAY-HUUCEWRRSA-N naxagolide Chemical compound C1=C(O)C=C2[C@H]3OCCN(CCC)[C@@H]3CCC2=C1 JCSREICEMHWFAY-HUUCEWRRSA-N 0.000 claims description 3
- QVYRGXJJSLMXQH-UHFFFAOYSA-N orphenadrine Chemical compound C=1C=CC=C(C)C=1C(OCCN(C)C)C1=CC=CC=C1 QVYRGXJJSLMXQH-UHFFFAOYSA-N 0.000 claims description 3
- 229960003941 orphenadrine Drugs 0.000 claims description 3
- 150000007925 phenylethylamine derivatives Chemical class 0.000 claims description 3
- 229960005253 procyclidine Drugs 0.000 claims description 3
- 230000001975 sympathomimetic effect Effects 0.000 claims description 3
- 229940064707 sympathomimetics Drugs 0.000 claims description 3
- 229960004558 terguride Drugs 0.000 claims description 3
- 229960001032 trihexyphenidyl Drugs 0.000 claims description 3
- METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
- BDNMABJZSXTKAQ-VCPDFFEISA-N 3-(diethylamino)propyl (1r,4s)-3-phenylbicyclo[2.2.1]heptane-3-carboxylate Chemical compound CCN(CC)CCCOC(=O)C1([C@H]2CC[C@H](C2)C1)C1=CC=CC=C1 BDNMABJZSXTKAQ-VCPDFFEISA-N 0.000 claims description 2
- 229960002274 atenolol Drugs 0.000 claims description 2
- 239000002876 beta blocker Substances 0.000 claims description 2
- 229940097320 beta blocking agent Drugs 0.000 claims description 2
- 229960003003 biperiden Drugs 0.000 claims description 2
- YSXKPIUOCJLQIE-UHFFFAOYSA-N biperiden Chemical compound C1C(C=C2)CC2C1C(C=1C=CC=CC=1)(O)CCN1CCCCC1 YSXKPIUOCJLQIE-UHFFFAOYSA-N 0.000 claims description 2
- 229960001793 bornaprine Drugs 0.000 claims description 2
- 239000003954 decarboxylase inhibitor Substances 0.000 claims description 2
- 229960004851 pergolide Drugs 0.000 claims description 2
- YEHCICAEULNIGD-MZMPZRCHSA-N pergolide Chemical compound C1=CC([C@H]2C[C@@H](CSC)CN([C@@H]2C2)CCC)=C3C2=CNC3=C1 YEHCICAEULNIGD-MZMPZRCHSA-N 0.000 claims description 2
- 229960002508 pindolol Drugs 0.000 claims description 2
- 239000003149 muscarinic antagonist Substances 0.000 claims 5
- PHUTUTUABXHXLW-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=NC=C[C]12 PHUTUTUABXHXLW-UHFFFAOYSA-N 0.000 claims 1
- 239000000126 substance Substances 0.000 abstract description 21
- 238000002648 combination therapy Methods 0.000 abstract description 10
- 230000000694 effects Effects 0.000 abstract description 9
- 239000010410 layer Substances 0.000 description 15
- 239000011159 matrix material Substances 0.000 description 11
- 239000000203 mixture Substances 0.000 description 8
- 229920000642 polymer Polymers 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 6
- 230000001078 anti-cholinergic effect Effects 0.000 description 6
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 6
- 229940052764 dopaminergic anti-parkinson drug mao b inhibitors Drugs 0.000 description 6
- 230000036470 plasma concentration Effects 0.000 description 6
- 238000004519 manufacturing process Methods 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 4
- 208000019430 Motor disease Diseases 0.000 description 4
- 239000002585 base Substances 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 229940127523 NMDA Receptor Antagonists Drugs 0.000 description 3
- 206010044565 Tremor Diseases 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000000812 cholinergic antagonist Substances 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 229960003638 dopamine Drugs 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 150000002191 fatty alcohols Chemical class 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 2
- 239000004831 Hot glue Substances 0.000 description 2
- 102000010909 Monoamine Oxidase Human genes 0.000 description 2
- 108010062431 Monoamine oxidase Proteins 0.000 description 2
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 2
- 206010034010 Parkinsonism Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PPBRXRYQALVLMV-UHFFFAOYSA-N Styrene Chemical compound C=CC1=CC=CC=C1 PPBRXRYQALVLMV-UHFFFAOYSA-N 0.000 description 2
- 239000000219 Sympatholytic Substances 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 2
- 229940092732 belladonna alkaloid Drugs 0.000 description 2
- BNQDCRGUHNALGH-UHFFFAOYSA-N benserazide Chemical compound OCC(N)C(=O)NNCC1=CC=C(O)C(O)=C1O BNQDCRGUHNALGH-UHFFFAOYSA-N 0.000 description 2
- 229960000911 benserazide Drugs 0.000 description 2
- 229960001081 benzatropine Drugs 0.000 description 2
- GIJXKZJWITVLHI-PMOLBWCYSA-N benzatropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(C=1C=CC=CC=1)C1=CC=CC=C1 GIJXKZJWITVLHI-PMOLBWCYSA-N 0.000 description 2
- GERIGMSHTUAXSI-UHFFFAOYSA-N bis(8-methyl-8-azabicyclo[3.2.1]octan-3-yl) 4-phenyl-2,3-dihydro-1h-naphthalene-1,4-dicarboxylate Chemical compound CN1C(C2)CCC1CC2OC(=O)C(C1=CC=CC=C11)CCC1(C(=O)OC1CC2CCC(N2C)C1)C1=CC=CC=C1 GERIGMSHTUAXSI-UHFFFAOYSA-N 0.000 description 2
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- 230000003291 dopaminomimetic effect Effects 0.000 description 2
- 229920001971 elastomer Polymers 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000005038 ethylene vinyl acetate Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 229960002715 nicotine Drugs 0.000 description 2
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 2
- 229940126701 oral medication Drugs 0.000 description 2
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000005060 rubber Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 230000000948 sympatholitic effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- KWTSXDURSIMDCE-MRVPVSSYSA-N (R)-amphetamine Chemical compound C[C@@H](N)CC1=CC=CC=C1 KWTSXDURSIMDCE-MRVPVSSYSA-N 0.000 description 1
- KQHZEKNQJJSVDN-KVVVOXFISA-N 2-(2-hydroxyethylamino)ethanol;(z)-octadec-9-enoic acid Chemical compound OCCNCCO.CCCCCCCC\C=C/CCCCCCCC(O)=O KQHZEKNQJJSVDN-KVVVOXFISA-N 0.000 description 1
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N 2-Propenoic acid Natural products OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 229930000680 A04AD01 - Scopolamine Natural products 0.000 description 1
- 102000004031 Carboxy-Lyases Human genes 0.000 description 1
- 108090000489 Carboxy-Lyases Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000015554 Dopamine receptor Human genes 0.000 description 1
- 108050004812 Dopamine receptor Proteins 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 1
- VQTUBCCKSQIDNK-UHFFFAOYSA-N Isobutene Chemical group CC(C)=C VQTUBCCKSQIDNK-UHFFFAOYSA-N 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 1
- 229920003171 Poly (ethylene oxide) Chemical class 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 229940035678 anti-parkinson drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000000939 antiparkinson agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000000768 catecholaminergic effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 235000010944 ethyl methyl cellulose Nutrition 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000010579 first pass effect Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229950005223 levamfetamine Drugs 0.000 description 1
- 229960004502 levodopa Drugs 0.000 description 1
- 108010009400 levodopa receptor Proteins 0.000 description 1
- 150000002646 long chain fatty acid esters Chemical class 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 229960001252 methamphetamine Drugs 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- IYETZZCWLLUHIJ-UHFFFAOYSA-N methyl-(1-phenylpropan-2-yl)-prop-2-ynylazanium;chloride Chemical compound Cl.C#CCN(C)C(C)CC1=CC=CC=C1 IYETZZCWLLUHIJ-UHFFFAOYSA-N 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229920003087 methylethyl cellulose Polymers 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000002887 neurotoxic effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037368 penetrate the skin Effects 0.000 description 1
- 230000035515 penetration Effects 0.000 description 1
- JZQKKSLKJUAGIC-UHFFFAOYSA-N pindolol Chemical compound CC(C)NCC(O)COC1=CC=CC2=C1C=CN2 JZQKKSLKJUAGIC-UHFFFAOYSA-N 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920003023 plastic Polymers 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920000058 polyacrylate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 229920000056 polyoxyethylene ether Polymers 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 239000004800 polyvinyl chloride Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 239000011241 protective layer Substances 0.000 description 1
- 238000004080 punching Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 229960002646 scopolamine Drugs 0.000 description 1
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 1
- 229960003678 selegiline hydrochloride Drugs 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000013464 silicone adhesive Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 229940127230 sympathomimetic drug Drugs 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 239000000057 synthetic resin Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229920001169 thermoplastic Polymers 0.000 description 1
- 239000004416 thermosoftening plastic Substances 0.000 description 1
- 230000009974 thixotropic effect Effects 0.000 description 1
- 229940127223 transdermally administered drug Drugs 0.000 description 1
- 230000003313 weakening effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/428—Thiazoles condensed with carbocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10338174A DE10338174A1 (de) | 2003-08-20 | 2003-08-20 | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| DE10338174.0 | 2003-08-20 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2005141214A RU2005141214A (ru) | 2006-07-27 |
| RU2397757C2 true RU2397757C2 (ru) | 2010-08-27 |
Family
ID=34201721
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2005141214/15A RU2397757C2 (ru) | 2003-08-20 | 2004-08-14 | Чрескожный лекарственный препарат для лечения болезни паркинсона, содержащий сочетания действующих веществ |
Country Status (21)
| Country | Link |
|---|---|
| US (1) | US8980308B2 (https=) |
| EP (1) | EP1656122B2 (https=) |
| JP (2) | JP2007502795A (https=) |
| KR (1) | KR20060065692A (https=) |
| CN (1) | CN1832732A (https=) |
| AT (1) | ATE446744T1 (https=) |
| AU (1) | AU2004266063B2 (https=) |
| BR (1) | BRPI0412054A (https=) |
| CA (1) | CA2535063C (https=) |
| DE (2) | DE10338174A1 (https=) |
| DK (1) | DK1656122T4 (https=) |
| ES (1) | ES2335771T5 (https=) |
| IL (1) | IL173712A (https=) |
| MX (1) | MXPA06001815A (https=) |
| NZ (1) | NZ545593A (https=) |
| PL (1) | PL1656122T5 (https=) |
| PT (1) | PT1656122E (https=) |
| RU (1) | RU2397757C2 (https=) |
| SI (1) | SI1656122T2 (https=) |
| WO (1) | WO2005018619A1 (https=) |
| ZA (1) | ZA200509779B (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
| AU2005284908B2 (en) | 2004-09-13 | 2011-12-08 | Morningside Venture Investments Limited | Biosynchronous transdermal drug delivery |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| PL1907382T3 (pl) | 2005-07-26 | 2016-01-29 | Bial Portela & Ca Sa | Pochodne nitrokatecholowe jako inhibitory COMT |
| CN101032474B (zh) * | 2006-03-06 | 2011-02-16 | 重庆医药工业研究院有限责任公司 | 一种治疗或预防神经系统疾病的雷沙吉兰透皮贴片及其制备方法 |
| EP1845097A1 (en) | 2006-04-10 | 2007-10-17 | Portela & Ca., S.A. | Oxadiazole derivatives as COMT inhibitors |
| BRPI0721213B1 (pt) | 2007-01-31 | 2021-11-09 | Bial - Portela & Ca, S.A. | Uso de nitrocatecóis substituídos, e embalagem |
| RU2326660C1 (ru) * | 2007-03-14 | 2008-06-20 | Закрытое акционерное общество "Биологические исследования и системы" | Пероральный лекарственный препарат мемантин (варианты) и способ его получения (варианты) |
| CN103977003A (zh) | 2007-04-02 | 2014-08-13 | 帕金森氏病研究院 | 用于降低治疗的副作用的方法和组合物 |
| US20100092554A1 (en) * | 2007-04-24 | 2010-04-15 | Boehringer Ingelheim International Gmbh | Combination with an extended release tablet formulation containing pramipexole or a pharmaceutically acceptable salt thereof |
| ES2723729T3 (es) * | 2008-07-29 | 2019-08-30 | Bial Portela & Ca Sa | Régimen de administración de nitrocatecoles |
| PT2413912T (pt) | 2009-04-01 | 2019-06-11 | Bial Portela & Ca Sa | Formulações farmacêuticas compreendendo derivados de nitrocatecol e métodos para as produzir |
| KR101292768B1 (ko) * | 2010-04-23 | 2013-08-05 | 아이큐어 주식회사 | 경피 흡수 제제 |
| ES2608782T3 (es) | 2010-04-30 | 2017-04-17 | Teikoku Pharma Usa, Inc. | Composiciones transdérmicas de propinilaminoindano |
| DE102010024105A1 (de) * | 2010-06-17 | 2011-12-22 | Grünenthal GmbH | Transdermale Verabreichung von Memantin |
| US20140045900A1 (en) | 2011-02-11 | 2014-02-13 | Bial-Portela & Ca, S.A. | Administration regime for nitrocatechols |
| EP2705842A1 (en) * | 2012-09-05 | 2014-03-12 | Pharnext | Therapeutic approaches for treating parkinson's disease |
| EP2688561B1 (en) | 2011-03-24 | 2018-08-22 | Teikoku Pharma USA, Inc. | Transdermal compositions comprising an active agent layer and an active agent conversion layer |
| WO2013006643A1 (en) | 2011-07-06 | 2013-01-10 | The Parkinson's Institute | Compositions and methods for treatment of symptoms in parkinson's disease patients |
| JP5913614B2 (ja) | 2011-11-09 | 2016-04-27 | テイコク ファーマ ユーエスエー インコーポレーテッド | 皮膚新生物の処置方法 |
| JP6456143B2 (ja) | 2011-12-13 | 2019-01-23 | ノヴィファーマ，エス．アー． | カテコール−ｏ−メチル転移酵素阻害剤を調製するための中間体として有用な化学的化合物 |
| US20130197023A1 (en) * | 2012-01-27 | 2013-08-01 | California Institute Of Technology | Neuroprotection by pharmacological chaperoning of nicotinic acetylcholine receptors |
| AU2013338243B2 (en) | 2012-11-02 | 2016-09-29 | Teikoku Seiyaku Co., Ltd. | Propynylaminoindan transdermal compositions |
| WO2014210544A2 (en) | 2013-06-27 | 2014-12-31 | Cedars-Sinai Medical Center | Adrenoceptors antagonists for the prevention and treatment of neurodegenerative conditions |
| CN103622997A (zh) * | 2013-11-22 | 2014-03-12 | 内蒙古医科大学 | 包含谷氨酸受体阻断剂盐酸美金刚或其药学可接受的盐与β受体阻断剂的药物组合物 |
| EP2946775A1 (de) | 2014-05-20 | 2015-11-25 | LTS LOHMANN Therapie-Systeme AG | Lavendelöl enthaltendes transdermales therapeutisches System |
| RU2017120184A (ru) | 2014-11-28 | 2018-12-28 | БИАЛ - ПОРТЕЛА ЭНД Ка, С.А. | Лекарства для замедления течения болезни паркинсона |
| CN104510725B (zh) * | 2015-01-22 | 2021-04-27 | 中国药科大学 | 一种普拉克索周效透皮贴剂及其制备方法 |
| AU2016211330A1 (en) | 2015-01-28 | 2017-08-03 | Chrono Therapeutics Inc. | Drug delivery methods and systems |
| US10679516B2 (en) | 2015-03-12 | 2020-06-09 | Morningside Venture Investments Limited | Craving input and support system |
| CN114668747A (zh) * | 2016-10-07 | 2022-06-28 | 全崴生技股份有限公司 | 普拉克索经皮贴片系统与用法 |
| CA3049529A1 (en) | 2017-01-06 | 2018-07-12 | Chrono Therapeutics Inc. | Transdermal drug delivery devices and methods |
| US12459965B2 (en) | 2017-10-09 | 2025-11-04 | Compass Pathfinder Limited | Preparation of psilocybin, different polymorphic forms, intermediates, formulations and their use |
| GB2571696B (en) | 2017-10-09 | 2020-05-27 | Compass Pathways Ltd | Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced |
| US11596779B2 (en) | 2018-05-29 | 2023-03-07 | Morningside Venture Investments Limited | Drug delivery methods and systems |
| US12397141B2 (en) | 2018-11-16 | 2025-08-26 | Morningside Venture Investments Limited | Thermally regulated transdermal drug delivery system |
| US12377112B2 (en) | 2019-04-17 | 2025-08-05 | Compass Pathfinder Limited | Methods of treating neurocognitive disorders, chronic pain and reducing inflammation |
| US20240299501A1 (en) * | 2023-03-06 | 2024-09-12 | Xygenyx Inc. | Composition and methods of treatment using transdermal hormone supplementation |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4812481A (en) * | 1986-04-16 | 1989-03-14 | Degussa Aktiengesellschaft | Synergistic combination of amantadiene and selegiline |
| US5462746A (en) * | 1992-11-02 | 1995-10-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation |
| US5902601A (en) * | 1993-09-22 | 1999-05-11 | Lts Lohmann Therapie-Systeme Gmbh | Volatile active substance containing plaster that may be produced without solvents |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL72684A (en) | 1984-08-14 | 1989-02-28 | Israel State | Pharmaceutical compositions for controlled transdermal delivery of cholinergic or anticholinergic basic drugs |
| JPH0611698B2 (ja) | 1984-12-19 | 1994-02-16 | 大正製薬株式会社 | 貼付剤 |
| US4666441A (en) * | 1985-12-17 | 1987-05-19 | Ciba-Geigy Corporation | Multicompartmentalized transdermal patches |
| DE3710966A1 (de) | 1986-04-16 | 1987-12-03 | Degussa | Synergistische kombination von amantadin und selegilin |
| US4877618A (en) * | 1988-03-18 | 1989-10-31 | Reed Jr Fred D | Transdermal drug delivery device |
| GB8807504D0 (en) * | 1988-03-29 | 1988-05-05 | Sandoz Ltd | Improvements in/relating to organic compounds |
| US4963568A (en) * | 1989-05-31 | 1990-10-16 | Abbott Laboratories | Dopamine agonists |
| AU4673993A (en) * | 1992-07-28 | 1994-02-14 | Procter & Gamble Company, The | Pharmaceutical composition for topical use containing a crosslinked cationic polymer and an alkoxylated ether |
| US5744476A (en) * | 1994-06-27 | 1998-04-28 | Interneuron Pharmaceuticals, Inc. | Dopamine D1 agonists for the treatment of dementia |
| US5601839A (en) * | 1995-04-26 | 1997-02-11 | Theratech, Inc. | Triacetin as a penetration enhancer for transdermal delivery of a basic drug |
| GB9511366D0 (en) | 1995-06-06 | 1995-08-02 | Smithkline Beecham Plc | Novel formulations |
| CA2223588C (en) | 1995-06-07 | 2004-01-06 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
| US5807570A (en) * | 1995-09-29 | 1998-09-15 | Cygnus, Inc. | Transdermal administration of ropinirole and analogs thereof |
| US6929801B2 (en) * | 1996-02-19 | 2005-08-16 | Acrux Dds Pty Ltd | Transdermal delivery of antiparkinson agents |
| DE19626621A1 (de) | 1996-07-02 | 1998-01-08 | Hexal Ag | Pflaster zur transdermalen Anwendung von Pergolid |
| US5877173A (en) * | 1996-08-28 | 1999-03-02 | Washington University | Preventing neuronal degeneration in Alzheimer's disease |
| JPH11209271A (ja) | 1998-01-23 | 1999-08-03 | Nitto Denko Corp | 経皮吸収製剤 |
| US5945117A (en) * | 1998-01-30 | 1999-08-31 | Pentech Pharmaceuticals, Inc. | Treatment of female sexual dysfunction |
| FR2788982B1 (fr) | 1999-02-02 | 2002-08-02 | Synthelabo | Compositions pharmaceutiques contenant de la nicotine et leur application dans le sevrage tabagique |
| CA2359640C (en) | 1999-02-05 | 2008-11-18 | Cipla Limited | Topical sprays |
| WO2000074661A2 (en) | 1999-06-05 | 2000-12-14 | Noven Pharmaceuticals, Inc. | Solubility enhancement of drugs in transdermal drug delivery systems and methods of use |
| DE19938823A1 (de) | 1999-08-19 | 2001-02-22 | Boehringer Ingelheim Pharma | Medikamentöse Behandlung des Restless Leg Syndroms |
| FR2798065B1 (fr) | 1999-09-02 | 2003-09-05 | Assist Publ Hopitaux De Paris | Utilisation de la nicotine ou de ses derives dans un medicament pour le traitement des maladies neurologiques, notamment la maladie de parkinson |
| JP2002097137A (ja) | 2000-07-19 | 2002-04-02 | Junichi Sudo | パーキンソン病の予防および／または治療剤 |
| US20070225379A1 (en) * | 2001-08-03 | 2007-09-27 | Carrara Dario Norberto R | Transdermal delivery of systemically active central nervous system drugs |
| DE10043321B4 (de) | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
| US20030119884A1 (en) * | 2000-11-01 | 2003-06-26 | Epstein Mel H. | Methods and compositions for regulating memory consolidation |
| DE10064453A1 (de) | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
| CA2381630A1 (en) | 2001-04-23 | 2002-10-23 | Leonard Theodore Meltzer | Method for preventing dyskinesias |
| EP1256339B1 (en) | 2001-05-08 | 2003-10-15 | Schwarz Pharma Ag | Transdermal therapeutic system for Parkinson's disease inducing high plasma levels of rotigotine |
| ATE246919T1 (de) | 2001-05-08 | 2003-08-15 | Sanol Arznei Schwarz Gmbh | Verbessertes transdermales therapeutisches system zur behandlung von morbus parkinson |
| US6638981B2 (en) * | 2001-08-17 | 2003-10-28 | Epicept Corporation | Topical compositions and methods for treating pain |
| DE10338174A1 (de) | 2003-08-20 | 2005-03-24 | Lts Lohmann Therapie-Systeme Ag | Transdermale Arzneimittelzubereitungen mit Wirkstoffkombinationen zur Behandlung der Parkinson-Krankheit |
-
2003
- 2003-08-20 DE DE10338174A patent/DE10338174A1/de not_active Withdrawn
-
2004
- 2004-08-14 MX MXPA06001815A patent/MXPA06001815A/es active IP Right Grant
- 2004-08-14 RU RU2005141214/15A patent/RU2397757C2/ru not_active IP Right Cessation
- 2004-08-14 ES ES04764129T patent/ES2335771T5/es not_active Expired - Lifetime
- 2004-08-14 CN CNA2004800225495A patent/CN1832732A/zh active Pending
- 2004-08-14 AT AT04764129T patent/ATE446744T1/de active
- 2004-08-14 CA CA2535063A patent/CA2535063C/en not_active Expired - Fee Related
- 2004-08-14 KR KR1020067003176A patent/KR20060065692A/ko not_active Ceased
- 2004-08-14 DE DE502004010303T patent/DE502004010303D1/de not_active Expired - Lifetime
- 2004-08-14 BR BRPI0412054-0A patent/BRPI0412054A/pt not_active IP Right Cessation
- 2004-08-14 JP JP2006523588A patent/JP2007502795A/ja not_active Withdrawn
- 2004-08-14 EP EP04764129A patent/EP1656122B2/de not_active Expired - Lifetime
- 2004-08-14 WO PCT/EP2004/009136 patent/WO2005018619A1/de not_active Ceased
- 2004-08-14 SI SI200431317T patent/SI1656122T2/sl unknown
- 2004-08-14 PT PT04764129T patent/PT1656122E/pt unknown
- 2004-08-14 NZ NZ545593A patent/NZ545593A/en not_active IP Right Cessation
- 2004-08-14 PL PL04764129T patent/PL1656122T5/pl unknown
- 2004-08-14 US US10/568,941 patent/US8980308B2/en active Active
- 2004-08-14 AU AU2004266063A patent/AU2004266063B2/en not_active Ceased
- 2004-08-14 DK DK04764129.5T patent/DK1656122T4/da active
-
2005
- 2005-12-02 ZA ZA200509779A patent/ZA200509779B/en unknown
-
2006
- 2006-02-13 IL IL173712A patent/IL173712A/en not_active IP Right Cessation
-
2011
- 2011-12-16 JP JP2011275858A patent/JP5827114B2/ja not_active Expired - Lifetime
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4812481A (en) * | 1986-04-16 | 1989-03-14 | Degussa Aktiengesellschaft | Synergistic combination of amantadiene and selegiline |
| US5462746A (en) * | 1992-11-02 | 1995-10-31 | Lts Lohmann Therapie-Systeme Gmbh & Co. Kg | Patch for transdermal administration of volatile pharmaceutically active ingredients of chemically basic nature and a process for preparation |
| US5902601A (en) * | 1993-09-22 | 1999-05-11 | Lts Lohmann Therapie-Systeme Gmbh | Volatile active substance containing plaster that may be produced without solvents |
Non-Patent Citations (2)
| Title |
|---|
| Frederique Menzaghi et al., "Interactions between a Novel Cholinergic Ion Channel Agonist, SIB-1765F and L-DOPA in the Reserpine Model of Parkinson's Disease in Rats." Pharmacology And Experimental Therapeutics. Vol.280, Issue 1, 393-401, 1997. * |
| Timothy Schallert et al., "Excessive Bracing Reactions and Their Control by Atropine and L-DOPA in an Animal Analog of Parkinsonism" Experimental neurology 64, 33-43 (1979). * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2397757C2 (ru) | Чрескожный лекарственный препарат для лечения болезни паркинсона, содержащий сочетания действующих веществ | |
| US4818541A (en) | Transdermal delivery of enantiomers of phenylpropanolamine | |
| JP7003211B2 (ja) | 日に１回の取り替えによるフェンタニルの経皮投与 | |
| KR20150094588A (ko) | 로티고틴의 경피 투여용 멀티 데이 패치 | |
| CN113950356B (zh) | 含罗替戈汀的贴附剂 | |
| TWI742331B (zh) | 含羅替戈汀之貼附劑 | |
| EP3925606B1 (en) | Rotigotine stabilization method | |
| CN113710238A (zh) | 透皮治疗系统 | |
| CN101180018B (zh) | 用于治疗恶心的经皮的方法和贴片 | |
| US7323191B2 (en) | Transdermal warfarin system | |
| AU2013202352B2 (en) | Transdermal delivery systems comprising bupivacaine | |
| KR960011233B1 (ko) | 0차 흡수속도를 갖는 지속성 경피투여 제형 및 그 제조방법 | |
| HK40002940B (zh) | 包含哌甲酯或其盐的透皮递送系统及其方法 | |
| JP2019034905A (ja) | デヒドロ酢酸含有経皮吸収製剤 | |
| TW200820996A (en) | Transdermal method and patch for emesis | |
| CN108025077A (zh) | 经皮递送系统 | |
| KR20100117387A (ko) | 덱시부프로펜 및 툴로부테롤을 함유하는 신규 복합 경피흡수제 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20170815 |